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Detriment to cognitive function is suggested by some studies, but 
whether this risk changes based on age is unknown. The purpose 
of this project was to determine patterns of practice of PCI for 
both limited stage SCLC (LS-SCLC) and extensive stage SCLC (ES-
SCLC) across Canada with a focus on how age affects 
recommendations in clinical practice. 
Methods and Materials: A survey was created in English and 
French. It was approved and distributed through Canadian 
Association of Radiation Oncology (CARO) to all its radiation 
oncologist members. Answers were collected anonymously using 
Google Forms over a five week period. Descriptive statistics were 
used to analyze responses. 
Results: Fifty-seven responses were collected with 
representation from all CARO regions. Ninety-eight percent of 
respondents routinely would recommend PCI for LS-SCLC and 78% 
for ES-SCLC. For LS-SCLC, age was an independent factor for 
recommending PCI for 52% of respondents, and 65% used an age 
cut off of 80 – 84 years. For ES-SCLC, only 46% of respondents 
would consider age when recommending PCI, and 48% of those 
also used 80 – 84 years as the cut off. 85% justified this cut point 
based on poor patient outcome in their own or a colleague’s 
experience. Forty-two percent of respondents who didn't use an 
age cut off indicated that a patient's performance status was a 
more relevant criterion. 
Conclusions: Based on the consensus opinion from this survey, 
we would suggest PCI for SCLC should be offered to patients with 
acceptable performance status under 80 years of age. For 
patients 80 years and older, caution is recommended. 
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Purpose: The current standard of care for unresectable locally 
advanced Stage III non-small cell lung cancer (NSCLC) is 
chemoradiotherapy. However, there is no established consensus 
for the optimal chemotherapy regimen. We designed a Phase I 
study of docetaxel and cisplatin (DC) chemotherapy with 
concurrent thoracic radiotherapy (RT) followed by consolidative 
DC for locally advanced NSCLC. The primary objective of this 
study is to determine optimal concurrent and consolidative DC 
doses, with secondary objectives to describe associated 
toxicities. 
Methods and Materials:  Patients with histologically or 
cytologically proven and unresectable Stage IIIA or IIIB (dry) 
NSCLC were eligible for this single-institution research-ethics 
board approved study. In the concurrent cycles with thoracic RT, 
C was given every three weeks (fixed at 75mg/m2) and D given 
weekly. The starting dose of D was 20 mg/m2 weekly escalated 
in cohorts of three to define the maximum tolerated dose. RT 
was prescribed to a dose of 60 Gy in 30 fractions. This was 
followed by two cycles of consolidative DC, which were dose 
escalated if concurrent chemoradiotherapy was tolerated. 
Evaluation for dose limiting toxicities was performed on a weekly 
basis during RT. Tumour response was characterized through the 
RECIST criteria. Actuarial outcomes of overall survival (OS) and 
progression-free survival (PFS) were estimated using Kaplan-
Meier analysis. 
Results:  Between September 2004 to June 2014, 26 patients 
were enrolled. One patient did not receive protocol-specified 
treatment due to metastatic disease on baseline imaging. Of the 
eligible patients, 18 had Stage IIIA and seven had Stage IIIB 
disease. The median OS all patients was 33.6 months (95% CI 
15.8-71.6). Median PFS was 17.0 months (95% CI 9.2-26.3) with 
median follow up of 26.6 months (range 0.43 -110.8). The 
majority of patients (19/26) completed both phases of treatment 
and most received concurrent D at 20mg/m2 weekly. Eight 
patients tolerated dose escalation of posterior consolidative C or 
D. Twelve patients experienced Grade 3 toxicities (five 
esophagitis, one pneumonitis, three nausea, one leukopenia, and 
two neutropenia). Three patients had Grade 4 neutropenia. No 
patients died due to early or late treatment toxicities. Complete 
response, partial response, and stable disease were observed in 
one, 16 and four patients, respectively. Five patients underwent 
surgical resection, and three of five did not have evidence of 
residual disease. 
Conclusions:  Cisplatin and docetaxel (DC) chemotherapy with 
concurrent radiation treatment followed by consolidative DC 
achieved promising results in the treatment of Stage III NSCLC in 
light of reported outcomes from RTOG 0617 (standard arm 
median PFS 11.8, OS 28.7 months). However, treatment 
toxicities should be considered. The dose finding results of this 
study will inform the design of Phase II/III trials. 
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Purpose: Cutaneous squamous cell carcinoma (cuSCC) accounts 
for approximately 30% of all skin cancers and is one of the most 
common cancers in North America. The standard treatment for 
locally advanced cuSCC is surgery followed by adjuvant 
radiotherapy (RT). Patients presenting with locally advanced or 
recurrent disease are often elderly or immunosuppressed, and 
may be medically inoperable or technically unresectable. These 
patients are traditionally treated with radiotherapy alone since 
adding concurrent chemotherapy may not be well tolerated by 
this group. The risk of locoregional recurrence is about 40% for 
RT alone, compared to 15% in those treated by surgery and RT. 
Cetuximab is an antagonistic monoclonal chimeric IgG1 antibody 
that binds to the epidermal growth factor receptor (EGFR). EGFR 
overexpression in cuSCC varies between 43–100% of patients. 
Small, single institutional studies have retrospectively reported 
synergistic activity when combining Cetuximab and RT (CRT) for 
the treatment of metastatic or unresectable cuSCC. In 
preparation for a larger Phase II study, this project prospectively 
identified patients with unresectable cuSCC who were 
candidates for CRT. 
Methods and Materials: Three patients have been treated with 
CRT in the last 18 months. Data regarding patient outcome and 
tolerability was collected prospectively. Cetuximab was 
delivered weekly, with the first dose timed as a loading dose (400 
mg/m2) seven days prior to the initiation of radiotherapy. 
Concurrent with radiation, weekly doses of cetuximab were 
administered at a dose of 250 mg/m2. Radiation doses varied 
between patients (5500 cGy/22#, n = 1, and 6600 cGy/30#, n = 
2). 
Results: The median age in our cohort was 85 years. All were 
male patients, with Karnofsky performance scores ≥ 60. Two 
patients were treated for primary SCC (T3N0M0 and T3N1M0) 
while the third patient was treated for recurrent disease. 
Notably, one patient presented with Waldenstrom’s 
macroglobulinemia. Treatment was well tolerated, and felt to 
be comparable to treatment with RT alone. One patient 
developed a Grade 2 acneiform skin reaction likely related to 
cetuximab. One patient developed an acute coronary syndrome 
(Grade 3), most likely unrelated to therapy. Two patients had a 
complete response to treatment. The first patient is in remission 
for 18 months and the second patient is in remission for 12 
months. The third patient completed CRT two months ago and is 
waiting for reassessment.  
Conclusions: Despite the frailty of our cohort, CRT was well 
tolerated and produced exceptional clinical outcomes. 
Limitations to this study include its small sample size and non-
randomization. This study will serve as the basis for a larger, 
prospective, randomized Phase II study which is now in 
